Crossmark

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy

Crossref DOI link: https://doi.org/10.1186/s12885-025-14337-z

Published Online: 2025-05-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Shugui

Qiu, Zhengang

Shi, Huaqiu

Yu, Wei

Liu, Linfang

Wu, Longqiu

Zhong, Wenjuan
Funding

Funding for this research was provided by:

the Guiding Science and Technology Programme of Ganzhou City, China (S2024-NSLY-0481)
License Information

Text and Data Mining valid from 2025-05-23

Version of Record valid from 2025-05-23
More Information

Article History

Received: 11 March 2025

Accepted: 14 May 2025

First Online: 23 May 2025

Declarations

:

: The study was approved by the Ethics Committee of the First Affiliated Hospital of Gannan Medical College (LLSC-2024 NO.274) and informed consent was obtained from all study participants.This study involves research on human data and the study adheres to the Helsinki Declaration.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below